Methotrexate shows promise for treating juvenile scleroderma

01/8/2013 | PhysiciansBriefing.com

More than 70% of juvenile localized scleroderma patients who took oral methotrexate were in clinical remission for a mean of 25 months, while 27.1% experienced remission while taking the drug, according to an Italian study in the Journal of the American Academy of Dermatology. Generally mild side effects were reported by 48.3% of respondents, but they didn't cause the patients to stop the medication.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC